EQUITY (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2023

Dec. 31, 2022

Equity

Schedule of issued capital

	December 31,		June 30,
	2022		2023		2023
	CNY		CNY		US$
	(Audited)		(Unaudited)		(Unaudited)
Authorized:
10,000,000 preferred shares, no par value		—		—		—
200,000,000 common shares, no par value		—		—		—
Common shares issued and fully paid:
June 30, 2023: 8,197,897*, (December 31, 2022: 40,948,082) common shares, no par value		450,782		450,782		62,146

	December 31,
	2021		2022		2022
	CNY		CNY		US$
Authorized:
10,000,000 preferred shares, no par value		—		—		—
200,000,000 common shares, no par value		—		—		—
Common shares issued and fully paid:
December 31, 2022: 40,948,082* (December 31, 2021: 40,948,082) common shares, no par value		450,782		450,782		65,351

* The numbers of common shares above are before giving effect to the Share Combination which became effective on April 3, 2023. Refer to Note 31 for further details. 

Schedule of other capital reserves

	Other capital reserves
	CNY		US$
As of January 1, 2021	787,987		114,236
Deemed distribution to the controlling shareholder	(75,651	)	(10,967	)
Equity-settled share-based payment	2,311		335
Others	4,463		647
As of December 31, 2021	719,110		104,251
As of January 1, 2022	719,110		104,251
Equity inventive share-based payment (Note 27)	16,209		2,342
As of December 31, 2022	735,319		106,600

Schedule of share capital

	Number of shares			Share capital
				CNY		US$
As of January 1, 2022		40,948,082			450,782		62,146
Common shares issued through private placement		—			—		—
As of December 31, 2022 and January 1, 2023		40,948,082			450,782		62,146
Effect of Five-to-One Share Combination*		(32,750,185	)		—		—
As of June 30, 2023		8,197,897			450,782		62,146

* On April 3, 2023, the Company effected a share combination in which all of the Company's issued and outstanding ordinary shares were combined on a 5-to-1 basis. The basic and diluted earnings/(loss) per ordinary share has been retrospectively adjusted to reflect the impact of the share combination. All outstanding options, warrants and other rights to purchase the Company's common shares were adjusted proportionately as a result of the share combination.